孟鲁司特及特布他林联用对支气管哮喘患儿的疗效及症状评分的影响

摘要

目的:研究孟鲁司特及特布他林联用对支气管哮喘患儿的疗效及症状评分的影响.方法:选择自2014年6月到2016年12月在医院接受治疗的支气管哮喘患儿124例纳入本次研究.根据数字法将患儿分成观察组以及对照组各62例,两组均给予常规抗感染,吸氧,以及解痉平喘和支气管扩张等相关药物治疗.对照组另予以特布他林雾化吸入,观察组基于对照组的用药方式,另加服孟鲁司特.治疗2个月后对比两组疗效,肺功能指标(1s用力呼气容积FEV1、呼气峰值流速 PEF 及用力呼气量占用力肺活量比FEV1/FVC),症状评分以及不良反应.结果:观察组的临床控制率为40.32%,总有效率为98.39%,均分别显著高于对照组的17.74%和88.71%,差异有统计学意义(P<0.05).治疗后两组的FEV1、PEF及FEV1/FVC水平均分别显著高于治疗前,且观察组较对照组显著更高,差异均有统计学意义(P<0.05).治疗后两组的日间、夜间症状评分均分别显著低于治疗前,且观察组较对照组显著更低,差异均有统计学意义(P<0.05).观察组的不良反应总发生率是6.45%,与对照组的11.29%相比,差异无统计学意义(P>0.05).结论:孟鲁司特及特布他林联用对支气管哮喘患儿具有较好的疗效,还可有效改善其症状评分.%Objective:To study influence of effect and symptom scores of montelukast and terbutaline in the treatment of children patients with bronchial asthma. Methods: 124 children with bronchial asthma who were treated in our hospital from June 2014 to December 2016 were enrolled in this study. The children were divided into observation group and control group with 62 cases in each group,the two groups were given rou-tine anti infection, oxygen inhalation, and relieving asthma and bronchiectasis and other related drugs. The control group was treated with terbutaline inhalation,while the observation group based on the control group of the drug,plus taking montelukast. After 2 months of treatment,the curative effect of the treatment group was compared with that of the two groups(FEV1,PEF and FEV1/FVC),symptom scores and adverse reactions. Results:The clinical control rate of the observation group was 40.32%, the total effective rate was 98.39%, which were significantly higher than the control group of 17.74% and 88.71%,the difference was statistically significant (P <0.05). After treatment,the levels of FEV1,PEF and FEV1/FVC in the two groups were sig-nificantly higher than those before treatment, the observation group was significantly higher than the control group,the difference was statistically significant(P <0.05). After treatment,the two groups were significant-ly lower than those in the control group in the day and night symptom scores, and the observation group was significantly lower than the control group,the difference was statistically significant(P < 0.05). The total in-cidence of adverse reactions in the observation group was 6.45%,compared with the control group of 11.29%, the difference was not statistically significant (P > 0.05). Conclusion: Montelukast and terbutaline in the treatment of children with bronchial asthma has a good effect, but also can effectively improve the symptom score.